Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Elimusertib - Bayer

Next Previous
Drug Profile

Elimusertib - Bayer

Alternative Names: BAY-1895344; BAY-1895344 HCl

Latest Information Update: 02 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer
  • Developer Bayer; National Cancer Institute (USA)
  • Class Antineoplastics; Morpholines; Naphthyridines; Pyrazoles; Small molecules
  • Mechanism of Action ATR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours
  • Phase I Head and neck cancer; Lymphoma; Ovarian cancer

Most Recent Events

  • 01 Dec 2023 Bayer and GlaxoSmithKline terminates a Phase-I clinical trials in Solid tumours and Ovarian cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater, Recurrent, Combination therapy) in USA (PO) due to no anticipated benefits from experimental combinations (NCT04267939) (EudraCT2018-003930-34)
  • 11 Oct 2023 Bayer completes a Phase-I clinical trials in Lymphoma in US, Canada, China, Japan, Singapore, Switzerland, France and the UK (NCT03188965) (JapicCTI183998)(EudraCT2016-004484-39)
  • 02 Jun 2023 Pharmacokinetics and adverse events data from a phase I/II trial in Solid tumours presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top